i-SCOOP

Ideogram 4.0, open weight image model built for design work

Ideogram 4.0 is the first open weight text to image model from Ideogram, with JSON prompting, native 2K output and best in ...
The Globe and Mail

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor ...
manilatimes

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

MDNA113 is a novel IL-13Rα2 tumor-targeted and "masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK to the tumor ...
Yahoo Finance

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

TORONTO and HOUSTON, March 18, 2026 (GLOBE NEWSWIRE)-- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the ...
autoevolution

Mercedes-Benz Teases Refreshed S-Class Flagship While Talking About Robotaxi Partnership

Mercedes-Benz and Momenta have partnered with technology company K2 and its Abu Dhabi-based subsidiary, Lumo, to operate a fleet of robotaxi S-Class test vehicles. That's quite interesting in itself.
autoevolution

First Look: The Mercedes-Benz C-Class EQ Will Fight BMW's i3 and Has a Grille Just As Big

Mercedes-Benz has released the first official teaser of its upcoming all-electric C-Class, a model that will debut in 2026 and is being positioned directly against BMW's i3 electric sedan. Previewed ...
WAVY-TV

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR ...

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor ...